Vasgard

Quick links to important sections

Vasgard

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasgard

Vasgard

Vasgard is a prescription-only medicine whose active ingredient is Amlodipine, a synthetic compound derived from the dihydropyridine chemical structure. This medication is classified as a Calcium Channel Blocker (CCB), a major class of drugs used in cardiovascular medicine.

Amlodipine functions as a vasoselective calcium antagonist, primarily acting on the blood vessels. The compound is characterized by high bioavailability, which allows a significant amount of the medication to enter the systemic circulation to achieve its therapeutic effect. Its long-acting profile supports a once-daily dosing frequency, which facilitates consistent pressure management.


Amlodipine: Composition, Form, and General Purpose

The medication is administered via oral administration as a single-component product typically supplied in the tablet dosage form. The core composition of Vasgard features the active ingredient Amlodipine (often as the Amlodipine besylate salt), along with inert excipients that form the solid oral vehicle. This formulation is designed for patients requiring stable, continuous modulation of blood vessel tone.

The drug’s classification as a CCB means it modulates the flow of calcium ions into vascular smooth muscle cells. This action induces vessel relaxation, causing peripheral vasodilation. The general purpose of this mechanism is to decrease the overall resistance to blood flow within the systemic circulation, thereby reducing the mechanical workload on the heart and assisting in maintaining balanced vascular pressure—a crucial aspect of long-term pressure management.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Vasgard?

Possible Side Effects and Safety Information

The official safety profile for Vasgard (Amlodipine) outlines potential adverse reactions categorized by their frequency and the system-organ classes affected, as documented by regulatory authorities. The most frequently reported adverse reaction is Oedema (swelling), particularly peripheral oedema or ankle swelling, classified as Very Common.


Adverse reactions classified as Common include headache, somnolence (drowsiness), dizziness, palpitations, flushing, nausea, abdominal pain, and fatigue. These effects are often noted as being more common especially at the beginning of the treatment and may diminish on continued therapy.


Systemic Safety and Serious Reactions

Adverse effects are categorized across multiple body systems, including the Nervous system (dizziness, headache), Vascular system (flushing, hypotension), and Gastrointestinal system (nausea, altered bowel habits). Serious adverse reactions, though classified as Very Rare in official documents, include Myocardial infarction, Angioedema (severe swelling), Hepatitis, and severe skin conditions such as Stevens-Johnson syndrome.


Population-Specific Notes and Restrictions

Regulatory safety notes advise caution for certain populations. Clearance of Amlodipine is decreased in individuals with hepatic impairment (liver disease) and in older adults, where a lower initial dose may be considered due to potential increases in exposure. Amlodipine is contraindicated in cases of severe hypotension and hypersensitivity to the active substance or other dihydropyridine derivatives.

Overdose and Emergency Response

Vasgard (Amlodipine) overdose is documented in regulatory sources as potentially life-threatening due to the risk of severe circulatory instability. The primary documented presentation is marked and prolonged systemic hypotension resulting from excessive peripheral vasodilation. This can be accompanied by disturbances in heart rate, including both bradycardia (slow heart rate) and tachycardia (rapid heart rate).

Gross overdosage carries the severe risk of shock and fatal outcome. Regulatory labeling also highlights a potential for a delayed complication: non-cardiogenic pulmonary oedema, which may manifest up to 24 to 48 hours after ingestion.

When to Seek Help and Required Actions It is regulatory guidance that an individual must seek immediate medical attention for a suspected Vasgard overdose. Since no specific antidote is known, management is officially defined as symptomatic and supportive treatment. This emergency protocol requires active cardiovascular support, which may include procedural steps such as gastric decontamination (e.g., activated charcoal) and the use of vasoconstrictors like norepinephrine if severe hypotension is refractory to intravenous fluids. Due to the drug’s long half-life, extended clinical monitoring and observation in a hospital setting are required, even in cases where immediate symptoms appear minor.

Therapeutic Uses of Vasgard

Vasgard: Main Uses and Benefits

Vasgard (Amlodipine) is commonly used to help manage cardiovascular conditions and is relevant when supportive symptom management is appropriate. The medication is indicated to manage high blood pressure and certain types of angina. Its primary therapeutic application is in addressing chronic hypertension and preventing the symptoms of both Chronic Stable Angina and Vasospastic Angina.

“The medication may assist with easing the frequency and intensity of anginal episodes.”

Supporting Cardiovascular Stability

This domain addresses the foundational use of Vasgard in addressing chronic hypertension. This treatment is generally applied in conditions where symptoms related to systemic imbalance are present, even if often unnoticeable. The goal is to support consistent long-term pressure management, which may help ease the overall systemic burden and contributes to maintaining cardiovascular stability. For patients experiencing chest discomfort, this approach helps patients cope more steadily with symptoms related to physical discomfort, ultimately supporting them in maintaining functional stability and helping to improve day-to-day comfort.


Quick Fact: Relief for Episodic Chest Discomfort

Regulatory References

  1. Amlodipine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Use: Official Regulatory Rules

Official regulatory documents define specific population eligibility for Vasgard (Amlodipine).

Contraindications

The medicine is strictly contraindicated for patients with known hypersensitivity or allergy to amlodipine or other dihydropyridine derivatives. Use is also restricted or prohibited in conditions such as severe hypotension, cardiogenic shock, and obstructive left ventricular outflow tract disorders, according to some international regulatory bodies.


Age and Condition-Based Restrictions

Category Regulatory Status (Strictly Descriptive)
Age Eligibility Approved for adults and for hypertension in pediatric patients aged 6–17 years. Safety and efficacy are not established for children under six years old.
Hepatic Impairment Requires caution; a lower starting dose and slow titration are typically necessary due to the drug’s decreased clearance.
Renal Impairment The normal dosage is generally recommended, as changes in plasma concentration are not correlated with the degree of kidney function.
Pregnancy/Lactation Safety during pregnancy is not established, and use is only advised if the potential benefit justifies the risk. The label suggests discontinuing nursing or discontinuing the drug during lactation.

These official statements define the mandatory conditions and population-specific considerations for the medicine’s use, based solely on regulatory approval.

What should I know about interactions with other medicines?

Vasgard Interactions with other medicines and products

Based on available authoritative regulatory documents from major global health authorities, a comprehensive interaction profile for a medicinal product specifically named Vasgard is not explicitly detailed. The interactions listed below reflect general, documented principles of drug-drug interaction risk and are provided for educational context, given the lack of specific product-level information.


General Interaction Principles

Category Interaction Risk & Mechanism (General) Notes
Pharmaceutical Concurrent use of products with shared active ingredients Potential for dose stacking, leading to increased exposure and toxicity or adverse effects, requiring label cross-referencing.
Pharmacodynamic Combining CNS Depressants (e.g., alcohol, sedatives, some pain medications) Can lead to additive effects, significantly impairing alertness, reflexes, and motor skills, and potentially causing severe respiratory depression.
Pharmacokinetic Concomitant use with enzyme/transporter modulators Drugs that inhibit or induce specific cytochrome P450 (CYP) enzymes or drug transporters (e.g., P-gp) can alter the concentration of co-administered medicines, necessitating dose adjustment or close monitoring.

Interaction-Related Constraints

  • Condition-Specific Risk: Certain existing medical conditions (e.g., kidney or liver impairment) can increase a person's susceptibility to drug interactions, as they may alter the body's ability to process and eliminate one or both medicines.
  • Monitoring Required: Where there is an identified theoretical or known interaction risk, co-administration may require the monitoring of drug levels, therapeutic response, or adverse effects to maintain clinical safety and efficacy.

All patients should disclose their full list of medications, including prescription, over-the-counter, and herbal products, to their healthcare provider to screen for potential drug interactions.

Mechanism of Action

Vasgard is a selective, reversible inhibitor of the cysteine protease Cathepsin K (CTSK). This enzyme is highly expressed within the ruffled border of osteoclasts and functions as the primary collagenase responsible for the enzymatic degradation of the organic bone matrix during the bone resorption process. Vasgard binds non-covalently to the active site of CTSK, preventing the enzyme from performing the hydrolysis of Type I collagen and other non-collagenous proteins.

Inhibition of CTSK activity directly interrupts the osteoclast’s ability to dismantle the bone matrix, leading to a mechanistic cascade that reduces the overall rate of bone dissolution. This action modulates the molecular coupling mechanism between bone resorption and subsequent bone formation, resulting in a favorable shift in the overall bone remodeling balance. The pharmacological effect of Vasgard is confined to the inhibition of the resorption phase without exerting a direct influence on the activity or survival of bone-forming cells (osteoblasts).

Dosage and Administration Information

How to Use Vasgard

The administration of Vasgard (Amlodipine) is governed by protocols designed for chronic cardiovascular management. The medicine is for oral administration in the form of tablets available in 2.5 mg, 5 mg, and 10 mg strengths.


Official Dosing and Frequency

The standard adult protocol dictates once-daily dosing. The usual initial dose for the treatment of hypertension or angina is 5 mg once per day, with the maximum daily dose established at 10 mg.

Dose adjustments are procedural and must be undertaken slowly; established guidelines specify that a period of 7 to 14 days should elapse between any increase in dosage to ensure assessment at stable plasma levels.


Administration Specifics and Timing

Vasgard can be taken with or without food, providing flexibility in its daily administration. However, consistency is a key procedural rule: the medication should be taken at approximately the same time each day. If a dose is forgotten, the instruction is not to take a double dose to compensate, but instead to continue with the next scheduled administration.


Population-Specific Use Rules

Documented protocols outline specific usage rules for certain populations. For older adults, frail patients, and those with hepatic (liver) impairment, a lower starting dose of 2.5 mg once daily is advised. Similarly, for pediatric patients (ages 6-17) being treated for hypertension, the maximum daily dose is restricted to 5 mg.

These documented rules define the precise method of administration over time, ensuring adherence to the usage protocol.

Recent Clinical Evidence

Vasgard: Recent Clinical Evidence

Combined Therapy Studies

Research has been conducted to investigate whether the combined use of the two active components in Vasgard was evaluated for its association with changes in symptom levels in patients with Condition X. Studies were examined for their potential association with changes in levels of pain and inflammation, and focused on whether there was an association with a change in flare-up frequency.

One randomized controlled trial (RCT) documented that patients receiving the combined treatment showed an observation of a greater number of days with lower reported symptom severity compared to those receiving placebo. The primary outcome measure for this trial focused on the patient-reported severity scale (PRSS).

Additionally, research examined the difference in changes to long-term mobility when comparing this dual therapy to one component administered alone. The findings were mixed across different study populations, indicating that it is not yet clear whether the combination provides a consistently greater observation of benefit over monotherapy.

Efficacy and Timing

A recent meta-analysis indicated that an improvement was observed in patients within the first week of treatment. However, the analysis also noted that the magnitude of this observation varied significantly depending on the underlying cause and patient characteristics. Evidence remains limited regarding the long-term observation of symptom progression beyond one year of treatment.

Tolerability and Observed Events

Tolerability and observed events have been documented in most adult patients. However, study exclusion criteria and observed adverse events indicated a need for further study of its effects in individuals with kidney impairment. The population studied generally excluded patients with a history of liver complications.

Current evidence includes studies that focused on how this treatment was utilized in the context of acute flare-ups.

Frequently Asked Questions (FAQ)

Common questions about Vasgard (FAQ)


Q: How long does Vasgard stay in your system after taking it?

Official information on pharmacokinetics indicates that Vasgard (amlodipine) has a terminal elimination half-life of approximately 30 to 50 hours. This means it has a long half-life, meaning the body clears half of the medicine over an extended period. Stable therapeutic levels (known as steady-state) are typically reached after about 7 to 8 days of continuous daily dosing.


Q: Can Vasgard cause trouble sleeping?

While the official safety profile often lists somnolence (drowsiness) as a common side effect, some regulatory documents also mention insomnia, or trouble sleeping, as a less common reaction. Insomnia is typically noted as occurring in 0.01% to 1% of patients receiving the medicine.


Q: Does Vasgard interact with common pain relievers like ibuprofen?

Regulatory information indicates that when Vasgard (amlodipine) is taken with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, the blood pressure lowering effect of Vasgard may potentially be reduced. Because of this potential interaction, monitoring may be required to ensure the medicine remains effective.


Q: Are there any specific foods or drinks to avoid when using Vasgard?

Regulatory-linked consumer information often suggests caution or avoidance regarding large quantities of grapefruit or grapefruit juice. This is because grapefruit can affect the way your body processes the medicine, which may lead to increased levels of Vasgard in the blood. You may take Vasgard with or without other food, but consultation with a healthcare provider regarding grapefruit consumption is part of safe usage.


Q: Can Vasgard affect my liver function test results?

Yes, official safety data has documented that Vasgard has been associated with a low rate of temporary elevations in serum liver enzymes during therapy. In very rare instances, the medicine has been linked to clinically apparent acute liver injury. Patients with hepatic impairment (liver disease) are advised in official documents to use a lower starting dose.


Q: How quickly should I expect to notice any effects from Vasgard?

The time it takes for a full effect is related to how the medicine accumulates in the body. Peak plasma concentrations are typically reached between 6 and 12 hours after taking the tablet. Full, stable therapeutic effects (steady-state levels) are generally reached after about 7 to 8 days of daily dosing.


Q: Are there any vitamins or supplements that should not be taken with Vasgard?

Regulatory principles of interaction recommend caution when combining Vasgard with certain vitamins or supplements, especially herbal remedies. These products may sometimes alter the way the body processes the medicine, potentially changing its blood levels. Information on all products being used should be disclosed to a healthcare professional.


Q: Can I take Vasgard if I also have diabetes?

The drug has been studied in patients with diabetes mellitus. Regulatory documents do not list diabetes as a contraindication or specific constraint. However, monitoring blood sugar levels is a general consideration for patients with diabetes.


Q: Can Vasgard be taken long-term?

According to official regulatory guidance, Vasgard (amlodipine) is generally considered suitable for long-term administration. Its effectiveness in managing high blood pressure and chest pain has been shown to be maintained with chronic, once-daily use.


Q: How is the safety profile of Vasgard described in regulatory documents?

The safety profile is generally described in official documents as favorable and well-tolerated by most adult patients. The most common side effects are often related to the medicine’s action of widening blood vessels (vasodilation), such as swelling or headache. These effects are typically observed more often at the start of treatment.


Q: How is the evidence for Vasgard summarized in official research documents?

Clinical trials reviewed by regulatory bodies document the medicine's association with several therapeutic outcomes. The evidence supports the medicine’s ability to reduce blood pressure in patients with hypertension and to reduce the frequency of chest pain (angina).


Q: Does Vasgard interact with herbal supplements like St. John's Wort?

Official drug interaction databases indicate a potential interaction between Vasgard and the herbal supplement St. John's Wort. Co-administration of this supplement may reduce the concentration and effect of the medicine in the blood. This interaction may require clinical monitoring or dose adjustment, according to interaction databases.


Q: What is known about Vasgard's effect on male fertility?

Official prescribing information focuses on human use and does not establish a clear link to male fertility. However, pre-clinical studies conducted in male rats have documented a reduction in certain reproductive hormones. The clinical relevance of this observation to human males is not confirmed in regulatory documents.


Q: Does Vasgard interact with birth control pills?

Drug interaction principles suggest that co-administration of Vasgard with certain oral contraceptives may require monitoring in specific high-risk patients. This is because some combinations can potentially increase the risk of elevated potassium levels. Disclosure of all medications, including hormonal contraceptives, is important.


Q: Is it okay to drive or operate machinery while taking Vasgard?

Official safety information notes that Vasgard can cause side effects such as dizziness, somnolence (drowsiness), and fatigue. Official guidance advises that operating machinery or driving should be done with caution until the effects of the medicine on the individual are fully known.


Q: What happens if I miss a dose of Vasgard?

Regulatory instructions for a missed dose advise taking the dose as soon as it is remembered. However, if it is closer to the time of the next scheduled dose (for example, 12 hours since the missed dose), the missed dose should be skipped. Official instructions specify that a double dose should not be taken to make up for a missed dose.


Q: Is Vasgard used for anything else besides its main purpose?

In addition to treating high blood pressure (hypertension), the drug is approved by regulatory agencies for several other indications. These include chronic stable angina, vasospastic angina (Prinzmetal’s or Variant angina), and certain coronary artery disease conditions.


Q: What kind of research studies were done on Vasgard before it was approved?

Like all approved medicines, Vasgard underwent a rigorous regulatory process. This included pre-clinical (laboratory) studies followed by a series of human clinical trials—Phases I, II, and III. These studies were conducted to systematically evaluate the drug’s safety, optimal dosage, and efficacy profile prior to its approval.


Q: Does Vasgard help with cholesterol levels?

The single-component medicine Vasgard (amlodipine) does not primarily act as a cholesterol-lowering agent. However, due to the need for some patients to manage both blood pressure and cholesterol, the active ingredient is available in regulatory-approved fixed-dose combination products with statins (a class of cholesterol-lowering drugs).


Q: Is there any information about Vasgard use during pregnancy from official sources?

Yes, the FDA label includes a Pregnancy Category C designation for amlodipine. This designation indicates that animal studies have shown potential adverse effects on the fetus, and controlled studies in humans are not available. The medicine is only advised for use during pregnancy if the potential benefit is determined to justify the potential risk, as safety is not established in humans.


Q: Does Vasgard interact with grapefruit juice?

Yes, some regulatory-linked consumer information suggests caution or avoidance when consuming large quantities of grapefruit or grapefruit juice. Grapefruit can affect the way the body processes Vasgard, potentially leading to increased concentrations of the medicine in the blood. Consultation with a healthcare provider regarding grapefruit consumption is part of safe usage.


Q: What is the typical expected outcome when Vasgard is used for its main indication?

Regulatory documents state that for the treatment of hypertension, the expected outcome is the maintenance of a reduced blood pressure for at least 24 hours with once-daily dosing. When used for angina, the medicine is associated with a reduction in the symptoms and frequency of chest pain.


Q: Is it possible to be allergic to Vasgard?

Yes, official regulatory labeling lists a known hypersensitivity or allergic reaction to the active substance (amlodipine) or other drugs in the same chemical class (dihydropyridines) as a strict contraindication. A known allergy or hypersensitivity to the drug's components is an official contraindication.


Q: Can I use over-the-counter cold medicines with Vasgard?

Official drug interaction principles note that caution is required when using over-the-counter cold medicines, as many contain sympathomimetic agents (such as decongestants). These agents can potentially cause adverse cardiovascular effects, such as increasing heart rate or blood pressure, and official interaction principles suggest that these agents should be used cautiously with Vasgard.


Q: Does Vasgard affect blood sugar control?

Regulatory documentation does not list Vasgard as a medication that primarily affects blood sugar control in clinical trials. However, because it is commonly used by patients with co-existing diabetes, authoritative guidance emphasizes monitoring blood sugar levels for patients with diabetes.


Q: Is Vasgard associated with any rare but serious safety concerns?

Yes, the official safety profile classifies several side effects as 'Very Rare,' indicating an occurrence of less than 1 in 10,000 patients. These serious events include conditions such as myocardial infarction (heart attack), hepatitis (liver inflammation), and severe skin conditions like Stevens-Johnson syndrome.


Q: What is the difference between Vasgard and other medicines in the same class?

Vasgard (amlodipine) is classified as a dihydropyridine calcium channel blocker (CCB). The difference within this class relates to selectivity: dihydropyridine CCBs are primarily selective for blood vessels. This distinguishes it from non-dihydropyridine CCBs, which also affect the heart's electrical conduction system.


Q: Can I take Vasgard with my blood pressure medicine?

Regulatory labeling confirms that Vasgard (amlodipine) may be used alone or in combination with other antihypertensive agents for the treatment of high blood pressure. Combination therapy with other blood pressure medicines is a documented and approved use for many patients.


Q: Does taking Vasgard mean I can stop making lifestyle changes?

Authoritative guidance emphasizes that medicine is typically part of a comprehensive management plan for high blood pressure. This strategy often includes non-pharmacological interventions like diet and exercise, alongside medication.


Q: Is Vasgard commonly prescribed for preventative purposes?

Yes, regulatory documentation confirms that the medicine is approved for certain preventative uses. Specifically, it is approved to lower the risk of hospitalization for angina and certain necessary heart procedures (like coronary revascularization) in patients with recently documented coronary artery disease.

How should Vasgard be stored and disposed of?

How to Store and Dispose of Vasgard?

Vasgard (amlodipine/valsartan) must be stored and handled according to specific regulatory requirements to maintain product stability and ensure public safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, typically 25 C (77 F), with excursions permitted between 15 C and 30 C (59 F to 86 F). Do not freeze.
Protection Keep the medicine in the original container, tightly closed, and protected from light and excess moisture.
Child Safety The medication must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Vasgard must not be disposed of in household waste or via wastewater.

Disposal must be done in accordance with local requirements, which often involves returning the product to a pharmacist or using an approved drug take-back program to avoid environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasgard found in:

A-Z Index: